CervoMed Inc.

About CervoMed Inc.

CervoMed is a clinical-stage company focused on developing treatments for neurodegenerative diseases. Their mission is to intervene early in the disease process to reverse synaptic dysfunction, which they believe is responsible for disease symptoms and progression before nerve cell death, particularly in conditions affecting memory, focus, and thinking.

Products & Services

Neflamapimod:An investigational, orally administered, small molecule brain penetrant that inhibits the protein kinase p38 alpha, aimed at reversing synaptic dysfunction in neurodegenerative diseases. It is currently in Phase 2 trials for Dementia with Lewy Bodies (DLB).

Specialties

Neurodegenerative Diseases Dementia with Lewy Bodies (DLB) Frontotemporal Dementia (FTD) Stroke Recovery Synaptic Dysfunction Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2024-03-28 FD: 2024-03-28	4 investors

Private Placement Latest

2024-03-28

$50.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

O

Ole Isacson

PhD, Chair of SAB

L

Lewis Cantley

Director of the Sandra and Edward Meyer Cancer Center and Professor of Cancer Biology in Medicine at Weill Cornell Medical College

J

Jeffrey Cummings

MD, ScD

H

Heidi McBride

Canada Research Chair in Mitochondrial Cell Biology and Professor in the Department of Neurology and Neurosurgery at McGill University

M

Matthew Winton

Chief Commercial and Business Officer

J

Joshua Boger

Chair Of The Board

View 15 more team members with Pro

Unlock Full Team Directory

Recent News

CervoMed Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised